GlassScriptPhysician profile
Mandy L Mcnamara
NPI 1376904136
$2,390.37
in general payments reported to CMS, 2019-2025
30 companies · $505 in 2025
The $505 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $188 · 2022: $257 · 2023: $805 · 2024: $636 · 2025: $505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,845.14 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $489.87 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $276.28 | 2023-2025 | Veozah |
| Lilly USA, LLC | $254.11 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $202.53 | 2023-2025 | |
| Abbvie INC. | $165.11 | 2021-2025 | |
| Exact Sciences Corporation | $151.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $97.69 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $96.55 | 2023-2024 | Evenity, Prolia |
| Glaxosmithkline, LLC. | $75.53 | 2023-2024 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.68 | 2022-2024 | Jardiance |
| Abbott Laboratories | $52.10 | 2023-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $43.16 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $39.18 | 2023 | Rexulti |
| Becton, Dickinson and Company | $38.80 | 2024-2025 | Bd Max System, Bd Max Instrument |
| Gilead Sciences, INC. | $36.50 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $36.36 | 2021-2025 | Gvoke Hypopen |
| Dexcom, INC. | $31.02 | 2021 | |
| Esperion Therapeutics, INC. | $23.20 | 2025 | Nexletol |
| Ucb, INC. | $22.60 | 2023 | Briviact |
| Sumitomo Pharma America, INC. | $22.47 | 2025 | Gemtesa |
| Neos Therapeutics, LP | $22.17 | 2023 | Adzenys Xr-Odt |
| Lifescan, INC. | $22.10 | 2021 | |
| Axsome Therapeutics, INC. | $21.81 | 2023 | Sunosi |
| Seqirus USA INC | $18.68 | 2024 | Flucelvax, Fluad |
| Biohaven Pharmaceuticals, INC. | $16.67 | 2021 | |
| Insulet Corporation | $15.34 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.11 | 2024 | |
| Idorsia Pharmaceuticals US INC | $13.57 | 2023 | Quviviq |
| Philips North America LLC | $12.87 | 2022 | |
| Mannkind Corporation | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Mcnamara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.